What is Orgenesis Price-to-Operating-Cash-Flow?
As of today (2024-04-25), Orgenesis's share price is $0.5001.
Orgenesis's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.54. Hence, Orgenesis's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Orgenesis's Price-to-Operating-Cash-Flow or its related term are showing as below:
Orgenesis's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.02.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.54.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 48.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -11.50% per year.
During the past 13 years, Orgenesis's highest 3-Year average Operating Cash Flow per Share Growth Rate was 48.10% per year. The lowest was -518.40% per year. And the median was -23.20% per year.
Orgenesis Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Orgenesis's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis Price-to-Operating-Cash-Flow Chart
|
Orgenesis Annual Data
|
|
Trend |
Nov14 |
Nov15 |
Nov16 |
Nov17 |
Nov18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Orgenesis Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Orgenesis's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Orgenesis's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orgenesis's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Orgenesis's Price-to-Operating-Cash-Flow falls into.
Orgenesis Price-to-Operating-Cash-Flow Calculation
Orgenesis's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.5001 | / | -0.538 |
| = | |
Orgenesis's Share Price of today is $0.5001.
Orgenesis's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Orgenesis (Orgenesis) Business Description
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
| Elliot Maltz |
officer: Chief Financial Officer |
C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116 |
| Jacob Safier |
10 percent owner |
C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004 |
| Efrat Assa Kunik |
officer: Chief Development Officer |
C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
| David Sidransky |
director |
JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205 |
| Mario Philips |
director |
C/O ATMI, INC, DANBURY CT 06810 |
| Sarah Ferber |
officer: Chief Scientific Officer |
17B HAHASKALA STREET, TEL AVIV L3 67890 |
| Guy Yachin |
director |
7 ORCHARD WAY N, POTOMAC MD 20854 |
| Yaron Adler |
director |
4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710 |
| Vered Caplan |
officer: CEO |
20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280 |
| Universite Libre De Bruxelles |
10 percent owner |
AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050 |
| Olivier Belenger |
10 percent owner |
DIEWEG, 69, BRUSSELS C9 1070 |
| Ii Sa Theodorus |
10 percent owner |
ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070 |
| Sca Theodorus |
10 percent owner |
ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070 |
| Denis Bedoret |
officer: See Remarks |
48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041 |
| Ashish Nanda |
director |
2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452 |
Orgenesis (Orgenesis) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ORGS has been successfully added to your